MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
0.6090
+0.0038 (0.63%)
At close: Aug 1, 2025, 4:00 PM
0.6109
+0.0019 (0.32%)
After-hours: Aug 1, 2025, 6:12 PM EDT

Company Description

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.

It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.

The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia.

It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726.

The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024.

MetaVia Inc. is headquartered in Cambridge, Massachusetts.

MetaVia Inc.
MetaVia logo
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees9
CEOHeon Kim Hyung

Contact Details

Address:
545 Concord Avenue, Suite 210
Cambridge, Massachusetts 02138
United States
Phone857 702 9600
Websitemetaviatx.com

Stock Details

Ticker SymbolMTVA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001638287
ISIN NumberUS64132R4048
Employer ID47-2389984
SIC Code2834

Key Executives

NamePosition
Heon Kim HyungChief Executive Officer, President and Director
Marshall H. WoodworthChief Financial Officer
Dr. Mi-Kyung KimChief Scientific Officer
Robert HomolkaSenior Vice President of Clinical Operations
Dr. W. Christopher Fang M.D.Consulting Chief Medical Officer and Advisor
Michael PineSenior Vice President of Business Development Advisor

Latest SEC Filings

DateTypeTitle
Jul 10, 2025EFFECTNotice of Effectiveness
Jul 10, 2025424B3Prospectus
Jul 9, 20258-KCurrent Report
Jul 2, 2025S-3Registration statement under Securities Act of 1933
Jun 30, 20258-KCurrent Report
Jun 10, 2025ARSFiling
Jun 10, 2025DEF 14AOther definitive proxy statements
May 30, 20258-KCurrent Report
May 27, 2025PRE 14AOther preliminary proxy statements
May 21, 20258-KCurrent Report